Alamar Biosciences Reports Q2 2026 Financial Results

Fremont, Calif., USA -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, reported its financial results for the second quarter ended June 30, 2026, delivering strong revenue growth and expanding its product portfolio.

Total revenue for the second quarter of 2026 reached $29.4 million, representing an 82% increase compared to $16.2 million in the same period of 2025. The growth was largely propelled by a 147% increase in consumable revenue, driven by strong demand for multiplex panels.

Financial Highlights

• Total Revenue: $29.4 million, up 82% year-over-year.
• Product Revenue: $23.3 million compared to $12.0 million in Q2 2025.
• Gross Margin: 60% for the quarter, compared to 53% in the prior-year period.
• Net Loss: $13.2 million, compared to a net loss of $7.0 million in Q2 2025.
• Cash Position: Cash, cash equivalents, short-term investments, and restricted cash totaled $256.3 million as of June 30, 2026.

Alamar Biosciences also reaffirmed its full-year 2026 revenue guidance, expecting it to be in the range of $116 million to $120 million, representing a 59% growth at the midpoint compared to 2025.